Goldenwell Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:34 pm EST
Share
Goldenwell Biotech, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.000382 million compared to USD 0.04369 million a year ago. Net loss was USD 0.035406 million compared to USD 0.004584 million a year ago.
For the nine months, sales was USD 0.00208 million compared to USD 0.0478 million a year ago. Net loss was USD 0.096096 million compared to USD 0.064764 million a year ago.
Goldenwell Biotech, Inc. is in the development stage whose purpose is research and development, production and sales health cares and supplements products. The Company is offering its products under two categories: Polypeptide Freeze-dried Powder and Solid Tablets Products. The Companyâs products are JI MAI-Bovine Cardiac Vascular Active Peptide, Double Proline AG- three-dimensional (3D) Active Collagen Peptide, Cartilage Peptide-Type II collagen peptide, Se Plus, and Sugar Master. Bovine cardiac vascular active peptide is a protein peptide of vascular homology (amino acid type and its sequence) which made from healthy and fresh bovine cardiac vascular tissues as raw materials. Its DPAG product is designed to be an easily absorbed bioactive collagen. Type II collagen peptide is prepared from Bovine or Pig Cartilage bones by hot water extraction. Its Sugar Master product is made utilizing low temperature extraction techniques to maximize the harvest of bio-actives of plant matter.
GOLDENWELL BIOTECH, INC. 
